Recs

1

Make Money in Biotech the Easy Way

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you expect the biotech industry to thrive as it develops new treatments for all kinds of health problems, the SPDR S&P Biotech (NYSE: XBI  ) ETF could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in several dozen of them simultaneously.

The basics
ETFs often sport lower expense ratios than their mutual fund cousins. The biotech ETF's expense ratio -- its annual fee -- is a relatively low 0.35%.

This ETF has performed well, beating the overall market handily over the past three and five years. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.

What's in it?
Several of this ETF's components made strong contributions to its performance over the past year. ARIAD Pharmaceuticals (Nasdaq: ARIA  ) , up 179% over the past year, has a promising immunosuppressant for cancer, ridaforolimus, in phase three trials, and stands to benefit from the salesforce power of its partner Merck (NYSE: MRK  ) . Regeneron Pharmaceuticals (Nasdaq: REGN  ) , which partnered with Sanofi (NYSE: SNY  ) to sell Zaltrap, saw its shares rise 101% over the past year. It owes that rise partly to news that Zaltrap, in conjunction with chemotherapy, helps patients with colon cancer.  

Other companies didn't add to the ETF's returns last year but could have an effect in the years to come. Dendreon (Nasdaq: DNDN  ) , for example, down 2% over the past year, has FDA approval for its new (though pricey) prostate cancer drug Provenge, but it hasn't been able to produce enough to meet demand. Human Genome Sciences (Nasdaq: HGSI  ) , down 5%, has finally brought a drug to market (Benlysta, for lupus), though profits may be a few years away.

The big picture
Demand for biotechnology isn't going away anytime soon. A well-chosen ETF can grant you instant diversification across the industry -- and make investing in and profiting from the sector that much easier.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

ETFs can help you find the way to better investing results. To find some great ETF investing ideas, take a look at The Motley Fool's special free report, "3 ETFs Set to Soar During the Recovery."

Longtime Fool contributor Selena Maranjian holds no position in any company mentioned. Click hereto see her holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. 


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 1507671, ~/Articles/ArticleHandler.aspx, 5/25/2012 5:33:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 8 hours ago Sponsored by:
DOW 12,529.75 33.60 0.27%
S&P 500 1,320.68 1.82 0.14%
NASD 2,839.38 -10.74 -0.38%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2012 4:00 PM
REGN $129.71 Up +2.16 +1.69%
Regeneron Pharmace… CAPS Rating: *
SNY $34.23 Up +0.13 +0.38%
Sanofi (ADR) CAPS Rating: *****
XBI $82.02 Up +0.92 +1.13%
SPDR S&P Biotech (… CAPS Rating: ***
MRK $37.60 Up +0.26 +0.70%
Merck & Co., Inc. CAPS Rating: ****
ARIA $16.85 Up +0.04 +0.24%
Ariad Pharmaceutic… CAPS Rating: ***
DNDN $7.22 Down -0.13 -1.77%
Dendreon Corp CAPS Rating: **
HGSI $13.62 Down -0.26 -1.87%
Human Genome Scien… CAPS Rating: **

Advertisement